April 6, 2018 / 10:04 AM / 6 months ago

BUZZ-Valeant: Mizuho does not see near term sell catalysts, upgrades stock

** “We see no near term sell catalysts and view 2018 guidance as achievable,” says Mizuho analyst Irina Koffler upgrading Valeant to “neutral” from “underperform”

** U.S.-listed shares of Canadian drugmaker up 0.8 pct at $15.92 premarket

** Says VRX’s diarrhea drug Xifaxan is showing strong growth, and number of pipeline catalysts ahead will provide additional momentum in 2018

** However, Koffler says VRX turnaround story is going to take much longer than expected and does not expect company to return to growth before 2020

** Kofflex, rated 3 out of 5 stars for recommendation accuracy on VRX by TR StarMine, raises PT by $5 to $15; median PT $17

** 5 of 19 brokerages rate the stock “buy” or higher, 9 “hold” and 5 “sell” or lower

** Stock down 24 pct this year so far (Reporting by Brijesh Patel in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below